Shareholder Alert: Ademi LLP investigates whether Meridian Bioscience, Inc. has obtained a Fair Price in its transaction with the Consortium

MILWAUKEE, July 7, 2022 /PRNewswire/ -- Ademi LLP is investigating Meridian (NASDAQ: VIVO) for possible breaches of fiduciary duty and other violations of law in its transaction with the Consortium. 

Click here to learn how to join the action: https://www.ademilaw.com/case/meridian-bioscience-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.

Ademi LLP alleges Meridian's financial outlook and prospects are excellent and yet Meridian holders will receive only $34.00 per share in an all-cash transaction valued at approximately $1.53 billion. The transaction agreement unreasonably limits competing bids for Meridian by imposing a significant penalty if Meridian accepts a superior bid. Meridian insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Meridian's board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Meridian.

If you own Meridian common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/meridian-bioscience-inc.                       

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP                                                          
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

SOURCE Ademi LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED